HBIO Harvard Bioscience, Inc. - Common Stock
$6.66
가격 · 8월 17, 2026
기준 재무 정보 8월 11, 2026
52주 범위
$0–$8
88% of range
애널리스트 평점
BUY
8 analysts
목표 주가
$8
+13% upside
P/E (TTM)
-0.5
ROE
-384.8%
순이익률
-65.5%
Harvard Bioscience, Inc. - Common Stock 정보 위키백과 회사 개요
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
더 보기
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.
History
Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.
The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.
In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.
From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.
In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.
The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.
In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).
In 2015 the company acquired HEKA Electronik of Germany.
In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.
In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.
James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.
For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.
In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.
In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.
Products
Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.
Finance
The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.
In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
HBIO 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$6.66
시가총액
$30M
P/E (TTM)
-0.5
EPS (TTM)
$-1.28
매출 (TTM)
$87M
배당 수익률
—
ROE
-384.8%
부채/자본
2.6
52주 범위
$0 – $8
HBIO 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$87M
2016-12-31
→
2025-12-31
EPS
$-1.28
2016-12-31
→
2025-12-31
잉여현금흐름
$5M
2018-12-31
→
2025-12-31
마진
-65.5%
2016-12-31
→
2025-12-31
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
HBIO
동종업계 중앙값
P/E (TTM)
-0.5
31.3
P/S (TTM)
0.3
0.5
P/B
2.2
1.3
EV / EBITDA
-1.2
—
Price / FCF (주가 / FCF)
5.4
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
HBIO
동종업계 중앙값
Gross Margin (매출 총이익률)
57.7%
47.0%
Operating Margin (영업이익률)
-56.1%
—
Net Profit Margin (순이익률)
-65.5%
-11.4%
ROA
-54.9%
-27.7%
ROE
-384.8%
-58.6%
ROIC
-96.8%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
HBIO
동종업계 중앙값
Debt / Equity (부채 / 자기자본 비율)
2.6
—
Current Ratio (유동비율)
2.2
1.7
Quick Ratio (당좌 비율)
1.1
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
HBIO
동종업계 중앙값
Revenue YoY (매출 YoY)
-8.1%
—
Revenue CAGR 3Y (매출 CAGR 3년)
-8.6%
—
Revenue CAGR 5Y (매출 CAGR 5년)
-3.2%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
HBIO
동종업계 중앙값
HBIO 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
8 명의 애널리스트
- 적극 매수 2 25.0%
- 매수 4 50.0%
- 보유 2 25.0%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
1 명의 애널리스트 · 2026-08-16
저가
$7.50
고가
$7.50
중앙값 목표
$7.50
+12.6%
평균 목표
$7.50
+12.6%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
0.05%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-0.14 | $-0.21 | 0.07% |
| 2026년 3월 31일 | $-0.33 | $-0.63 | 0.30% |
| 2025년 12월 31일 | $0.00 | $0.36 | -0.36% |
| 2025년 9월 30일 | $0.00 | $0.05 | -0.05% |
| 2025년 6월 30일 | $-0.10 | $-0.10 | 0.00% |
| 2025년 3월 31일 | $-0.10 | $-0.41 | 0.31% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| BNGO | $16M | -0.3 | -7.4% | -92.6% | -58.8% | — |
| CDT | — | — | — | — | — | — |
| BNBX | $6M | -0.0 | 1.1% | -709.5% | -264.9% | 39.3% |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Cost of Revenue | $37M | $39M | $46M | $53M | $51M | $44M | $52M | $58M | $38M | $56M | $60M | $59M | |
| Gross Profit | $50M | $55M | $66M | $61M | $68M | $58M | $64M | $63M | $39M | $48M | $49M | $49M | |
| R&D Expense | $9M | $10M | $12M | $12M | $11M | $9M | $11M | $11M | $6M | $5M | $6M | $5M | |
| SG&A Expense | $18M | $21M | $23M | $24M | $24M | $24M | $23M | $21M | $18M | $21M | $20M | $17M | |
| Operating Expenses | $98M | $61M | $64M | $68M | $66M | $58M | $64M | $62M | $40M | $51M | $50M | $43M | |
| Operating Income | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-635.0K | $-3M | $-2M | $7M | |
| Interest Expense | · | · | · | · | · | · | · | $5M | $713.0K | $639.0K | $846.0K | $990.0K | |
| Other Non-op | $-3M | $-325.0K | $-227.0K | $302.0K | $-666.0K | $-806.0K | $-469.0K | $-4M | $-739.0K | $-179.0K | $-1M | $-1M | |
| Pretax Income | $-57M | $-12M | $-3M | $-9M | $-140.0K | $-7M | $-6M | $-8M | $-3M | $-3M | $-4M | $4M | |
| Income Tax | $-686.0K | $740.0K | $859.0K | $337.0K | $148.0K | $518.0K | $-815.0K | $-4M | $-605.0K | $1M | $15M | $2M | |
| Net Income | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| EPS (Basic) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | $-0.01 | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| EPS (Diluted) | $-1.28 | $-0.28 | $-0.08 | $-0.23 | · | · | $-0.12 | $-0.08 | $-0.02 | $-0.13 | $-0.57 | $0.07 | |
| Shares (Basic) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 32,170,683 | |
| Shares (Diluted) | 44,391,000 | 43,538,000 | 42,420,000 | 41,413,000 | 40,343,000 | 38,640,000 | 37,813,580 | 36,453,126 | 34,753,325 | 34,211,521 | 33,592,775 | 33,236,569 | |
| EBITDA | $-49M | $-6M | $2M | $-7M | $2M | $221.0K | $377.0K | $984.0K | $-101.0K | $-3M | $-2M | · |
대차대조표 28
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $4M | $4M | $5M | $8M | $8M | $8M | $8M | $6M | $6M | $7M | $14M | |
| Receivables | $16M | $15M | $16M | $17M | $22M | $18M | $21M | $21M | $13M | $16M | $18M | $16M | |
| Inventory | $21M | $23M | $25M | $26M | $28M | $22M | $22M | $25M | $17M | $20M | $22M | $21M | |
| Other Current Assets | $3M | $3M | $4M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | |
| Current Assets | $48M | $45M | $49M | $51M | $62M | $52M | $54M | $58M | $48M | $45M | $51M | $57M | |
| PP&E (Net) | $5M | $5M | $4M | $3M | $3M | $4M | $5M | $6M | $4M | $4M | $6M | $5M | |
| PP&E (Gross) | $23M | $21M | $18M | $18M | $18M | $21M | $20M | $23M | $19M | $19M | $22M | $20M | |
| Accum. Depreciation | $18M | $16M | $14M | $15M | $14M | $17M | $15M | $17M | $16M | $15M | $16M | $15M | |
| Goodwill | $10M | $56M | $57M | $56M | $58M | $59M | $57M | $57M | $36M | $38M | $40M | $40M | |
| Intangibles | $8M | $11M | $16M | $21M | $27M | $33M | $38M | $46M | $10M | $17M | $21M | $21M | |
| Other Non-current Assets | $3M | $3M | $6M | $8M | $5M | $1M | $2M | $2M | $324.0K | $128.0K | $152.0K | $380.0K | |
| Total Assets | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Accounts Payable | $4M | $5M | $6M | $6M | $5M | $6M | $5M | $7M | $4M | $6M | $9M | $6M | |
| Accrued Liabilities | · | · | · | · | · | · | $6M | $7M | $4M | $5M | $4M | $4M | |
| Current Liabilities | $22M | $55M | $27M | $23M | $25M | $21M | $25M | $25M | $14M | $15M | $19M | $18M | |
| Capital Leases | $7M | $6M | $5M | $5M | $6M | $7M | $8M | · | · | · | · | · | |
| Deferred Tax | $317.0K | $710.0K | $776.0K | $590.0K | $2M | $2M | $2M | $2M | $3M | $6M | $4M | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $486.0K | $3M | $749.0K | $3M | · | · | · | · | |
| Total Liabilities | $66M | $63M | $64M | $73M | $79M | $80M | $83M | $86M | $28M | $36M | $42M | $40M | |
| Long-term Debt | $36M | $37M | $37M | $47M | $48M | $48M | $54M | $61M | $12M | $14M | $19M | $21M | |
| Total Debt | $36M | $37M | $37M | $47M | $49M | $48M | $50M | $59M | $9M | $11M | $16M | · | |
| Common Stock | $447.0K | $441.0K | $434.0K | $454.0K | $452.0K | $444.0K | $438.0K | $436.0K | $419.0K | $418.0K | $416.0K | $397.0K | |
| Retained Earnings | $-215M | $-158M | $-146M | $-142M | $-133M | $-132M | $-125M | $-120M | $-117M | $-116M | $-112M | $-93M | |
| Treasury Stock | · | · | · | · | $0 | $11M | · | · | · | · | · | · | |
| AOCI | $-12M | $-16M | $-14M | $-15M | $-10M | $-13M | $-13M | $-14M | $-11M | $-17M | $-12M | $-8M | |
| Stockholders' Equity | $14M | $63M | $73M | $72M | $83M | $77M | $82M | $83M | $81M | $72M | $78M | $95M | |
| Liabilities + Equity | $80M | $127M | $137M | $145M | $162M | $156M | $165M | $169M | $109M | $108M | $120M | $136M | |
| Shares Outstanding | 4,471,989 | 44,074,475 | 43,394,509 | 42,081,707 | 41,142,876 | 39,407,080 | 38,188,208 | 37,378,802 | 35,018,478 | 35,018,478 | 33,979,265 | 32,563,256 |
현금 흐름 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $4M | $5M | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $3M | $2M | |
| Deferred Tax | $-553.0K | $310.0K | $228.0K | $-498.0K | $-371.0K | $-143.0K | $-398.0K | $-4M | $-2M | $-279.0K | $15M | $1M | |
| Amort. of Intangibles | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $2M | $3M | $3M | $3M | |
| Restructuring | $200.0K | $800.0K | $391.0K | $2M | $1M | $2M | $1M | · | $0 | $-4.0K | $788.0K | $1M | |
| Operating Cash Flow | $7M | $1M | $14M | $1M | $1M | $9M | $8M | $3M | $1M | $5M | $705.0K | $4M | |
| CapEx | $1M | $3M | $2M | $2M | $1M | $1M | $1M | $986.0K | $890.0K | · | · | · | |
| Investing Cash Flow | $-2M | $-1M | $-2M | $-2M | $-1M | $-1M | $-229.0K | $-54M | $-917.0K | $-62.0K | $-8M | $-14M | |
| Debt Issued | $40M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $15M | $-6M | $-4M | $-3M | $-4M | $-67M | $-12M | $-20M | $-5M | $-9M | $-8M | · | |
| Stock Issued | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | $2M | |
| Net Stock Activity | · | · | · | · | · | · | · | $5M | $160.0K | $182.0K | $2M | · | |
| Financing Cash Flow | $-1M | $-131.0K | $-12M | $-3M | $-252.0K | $-8M | $-8M | $53M | $-2M | $-5M | $-540.0K | $-1M | |
| Net Change in Cash | $5M | $-175.0K | $-225.0K | $-3M | $-496.0K | $-18.0K | $162.0K | $2M | $137.0K | $-1M | $-7M | $-12M | |
| Taxes Paid | $-98.0K | $-159.0K | $207.0K | $534.0K | $577.0K | $416.0K | $374.0K | $98.0K | $13.0K | · | · | · | |
| Free Cash Flow | $5M | $-1M | $12M | $-438.0K | $67.0K | $8M | $7M | $2M | · | · | · | · | |
| Levered FCF | · | · | · | · | · | · | · | $-995.1K | · | · | · | · |
수익성 8
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% | 56.9% | 55.4% | 52.3% | 46.7% | 46.3% | 44.8% | · | |
| Operating Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| Net Margin | -65.5% | -13.2% | -3.0% | -8.4% | -0.24% | -7.6% | -4.0% | -2.4% | -0.85% | -4.1% | -17.5% | · | |
| Pretax Margin | -66.3% | -12.4% | -2.3% | -8.1% | -0.12% | -7.1% | -4.7% | -6.6% | -2.1% | -2.9% | -3.3% | · | |
| EBITDA Margin | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% | 0.22% | 0.32% | 0.81% | -0.10% | -2.9% | -1.6% | · | |
| ROA | -54.9% | -9.4% | -2.4% | -6.2% | -0.18% | -4.9% | -2.8% | -2.1% | -0.80% | -3.8% | -14.9% | · | |
| ROE | -384.8% | -19.3% | -4.6% | -13.2% | -0.36% | -10.2% | -5.9% | -3.6% | -1.1% | -5.8% | -22.0% | · | |
| ROIC | -96.8% | -6.6% | 2.3% | -6.0% | 3.2% | 0.19% | 0.24% | 0.37% | -0.05% | -5.0% | -9.6% | · |
유동성 및 지급능력 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 | 2.5 | 2.1 | 2.7 | 3.4 | 3.1 | 2.6 | · | |
| Quick Ratio | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 | 1.2 | 1.1 | 1.4 | 1.6 | 1.5 | 1.3 | · | |
| Debt / Equity | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| LT Debt / Equity | 2.6 | 0.0 | 0.4 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.1 | 0.2 | 0.2 | · | |
| Interest Coverage | · | · | · | · | · | · | · | 0.2 | -0.1 | -4.7 | -2.0 | · |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.7 | 0.9 | 0.9 | 0.9 | 0.8 | · | |
| Inventory Turnover | 1.7 | 1.6 | 1.8 | 1.9 | 2.1 | 2.0 | 2.2 | 2.7 | 2.6 | 2.7 | 2.8 | · | |
| Receivables Turnover | 5.6 | 6.1 | 6.8 | 5.9 | 6.0 | 5.3 | 5.5 | 6.9 | 6.4 | 6.3 | 6.5 | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -8.1% | -16.1% | -0.96% | -4.7% | 16.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -8.6% | -7.5% | 3.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -3.2% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 13
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $87M | $94M | $112M | $113M | $119M | $102M | $116M | $121M | $77M | $105M | $109M | $109M | |
| Net Income TTM | $-57M | $-12M | $-3M | $-10M | $-288.0K | $-8M | $-5M | $-3M | $-865.0K | $-4M | $-19M | $2M | |
| Market Cap | $30M | $93M | $232M | $117M | $290M | $169M | $116M | $119M | $116M | $105M | $118M | · | |
| Enterprise Value | $57M | $126M | $265M | $159M | $331M | $209M | $158M | $169M | $119M | $111M | $128M | · | |
| P/E | -0.5 | -7.5 | -66.9 | -12.0 | · | -20.4 | -25.4 | -39.8 | -165.0 | -23.5 | -6.1 | 81.0 | |
| P/S | 0.3 | 1.0 | 2.1 | 1.0 | 2.4 | 1.7 | 1.0 | 1.0 | 1.5 | 1.0 | 1.1 | · | |
| P/B | 2.2 | 1.5 | 3.2 | 1.6 | 3.5 | 2.2 | 1.4 | 1.4 | 1.4 | 1.5 | 1.5 | · | |
| P / Cash Flow | 4.5 | 64.6 | 16.5 | 101.2 | 229.8 | 18.1 | 14.5 | 41.2 | 109.3 | 19.5 | 167.2 | · | |
| P / FCF | 5.5 | -77.2 | 19.0 | -266.1 | 4329.2 | 20.7 | 17.1 | 62.6 | · | · | · | · | |
| EV / EBITDA | -1.2 | -20.3 | 139.8 | -23.0 | 160.1 | 945.8 | 419.8 | 172.2 | -1176.3 | -37.0 | -74.5 | · | |
| EV / FCF | 10.5 | -104.8 | 21.6 | -363.4 | 4938.0 | 25.6 | 23.2 | 89.3 | · | · | · | · | |
| EV / Revenue | 0.7 | 1.3 | 2.4 | 1.4 | 2.8 | 2.0 | 1.4 | 1.4 | 1.5 | 1.1 | 1.2 | · | |
| Earnings Yield | -191.0% | -13.3% | -1.5% | -8.3% | · | -4.9% | -3.9% | -2.5% | -0.61% | -4.3% | -16.4% | 1.2% |
손익계산서 16
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23M | $21M | $24M | $21M | $20M | $22M | $25M | $22M | $23M | $25M | $28M | $25M | $29M | $30M | $28M | $27M | |
| Cost of Revenue | $10M | $9M | $10M | $9M | $9M | $10M | $11M | $9M | $10M | $10M | $12M | $11M | $12M | $12M | $13M | $15M | |
| Gross Profit | $13M | $12M | $14M | $12M | $12M | $12M | $14M | $13M | $13M | $15M | $16M | $15M | $17M | $18M | $16M | $12M | |
| R&D Expense | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| SG&A Expense | $5M | $5M | $4M | $4M | $4M | $5M | $5M | $5M | $6M | $6M | $5M | $6M | $5M | $6M | $6M | $6M | |
| Operating Expenses | $14M | $13M | $12M | $12M | $12M | $62M | $14M | $15M | $15M | $17M | $16M | $16M | $16M | $17M | $16M | $16M | |
| Operating Income | $-978.0K | $-1M | $2M | $197.0K | $-819.0K | $-50M | $11.0K | $-2M | $-2M | $-2M | $282.0K | $-933.0K | $796.0K | $2M | $-457.0K | $-4M | |
| Other Non-op | $-125.0K | $-405.0K | $-1M | $-365.0K | $-434.0K | $-193.0K | $516.0K | $-518.0K | $-181.0K | $-142.0K | $-332.0K | $45.0K | $-372.0K | $432.0K | $465.0K | $-179.0K | |
| Pretax Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-51M | $590.0K | $-4M | $-3M | $-4M | $-1M | $-562.0K | $-2M | $1M | $-892.0K | $-5M | |
| Income Tax | $14.0K | $117.0K | $-357.0K | $97.0K | $28.0K | $-454.0K | $572.0K | $311.0K | $-353.0K | $210.0K | $715.0K | $677.0K | $-1M | $585.0K | $774.0K | $-1M | |
| Net Income | $-3M | $-3M | $-3M | $-1M | $-2M | $-50M | $18.0K | $-5M | $-3M | $-5M | $-2M | $-1M | $-980.0K | $622.0K | $-2M | $-3M | |
| EPS (Basic) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| EPS (Diluted) | $-0.64 | $-0.77 | $-0.06 | $-0.03 | $-0.52 | $-11.42 | $0.01 | $-0.11 | $-0.07 | $-0.11 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.04 | $-0.08 | |
| Shares (Basic) | 4,526,000 | 4,473,000 | -88,564,000 | 44,556,000 | 4,430,000 | 4,410,000 | -86,964,000 | 43,614,000 | 43,486,000 | 43,402,000 | -84,741,000 | 42,688,000 | 42,354,000 | 42,119,000 | -82,747,000 | 41,637,000 | |
| Shares (Diluted) | 4,526,000 | 4,473,000 | -88,564,000 | 44,556,000 | 4,430,000 | 4,410,000 | -86,964,000 | 43,614,000 | 43,486,000 | 43,402,000 | -85,405,000 | 42,688,000 | 42,354,000 | 42,783,000 | -84,003,000 | 41,637,000 | |
| EBITDA | $-978.0K | $-1M | · | $197.0K | $-819.0K | $-50M | · | $-2M | $-2M | $-2M | · | $-933.0K | $796.0K | $2M | · | $-4M |
대차대조표 26
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7M | $7M | $9M | $7M | $7M | $6M | $4M | $5M | $4M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | |
| Receivables | $14M | $15M | $16M | $12M | $12M | $13M | $15M | $13M | $12M | $15M | $16M | $15M | $17M | $18M | $17M | $15M | |
| Inventory | $22M | $22M | $21M | $22M | $22M | $23M | $23M | $26M | $25M | $24M | $25M | $26M | $26M | $27M | $26M | $26M | |
| Other Current Assets | $3M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $4M | $4M | $4M | $5M | $4M | $3M | $6M | |
| Current Assets | $46M | $47M | $48M | $44M | $45M | $45M | $45M | $47M | $46M | $48M | $49M | $50M | $53M | $52M | $51M | $52M | |
| PP&E (Net) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $3M | $3M | $3M | $3M | $4M | |
| PP&E (Gross) | · | · | $23M | · | · | · | $21M | · | · | · | $18M | · | · | · | $18M | · | |
| Accum. Depreciation | · | · | $18M | · | · | · | $16M | · | · | · | $14M | · | · | · | $15M | · | |
| Goodwill | $9M | $9M | $10M | $10M | $10M | $9M | $56M | $57M | $57M | $57M | $57M | $56M | $57M | $57M | $56M | $55M | |
| Intangibles | $6M | $7M | $8M | $8M | $9M | $10M | $11M | $12M | $13M | $15M | $16M | $17M | $18M | $20M | $21M | $22M | |
| Other Non-current Assets | $3M | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $5M | $6M | $8M | $6M | $8M | $8M | $8M | |
| Total Assets | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Accounts Payable | $6M | $5M | $4M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | |
| Current Liabilities | $25M | $24M | $22M | $54M | $55M | $56M | $55M | $23M | $23M | $26M | $27M | $24M | $23M | $23M | $23M | $21M | |
| Capital Leases | $6M | $6M | $7M | $7M | $7M | $7M | $6M | $7M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $6M | |
| Deferred Tax | $311.0K | $313.0K | $317.0K | $733.0K | $734.0K | $717.0K | $710.0K | $707.0K | $764.0K | $772.0K | $776.0K | $661.0K | $667.0K | $546.0K | $590.0K | $1M | |
| Other Non-current Liabilities | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $892.0K | $1M | $1M | $1M | $420.0K | |
| Total Liabilities | $69M | $68M | $66M | $64M | $64M | $65M | $63M | $66M | $62M | $64M | $64M | $65M | $68M | $71M | $73M | $75M | |
| Long-term Debt | $37M | $36M | $36M | $34M | $35M | $36M | $37M | $38M | $36M | $36M | $37M | $39M | $41M | $44M | $47M | $49M | |
| Total Debt | $37M | $36M | · | · | · | · | · | $38M | $36M | $36M | · | $39M | $42M | $44M | · | $50M | |
| Common Stock | $447.0K | $447.0K | $447.0K | $446.0K | $445.0K | $442.0K | $441.0K | $436.0K | $436.0K | $434.0K | $434.0K | $457.0K | $457.0K | $455.0K | $454.0K | $453.0K | |
| Retained Earnings | $-221M | $-218M | $-215M | $-212M | $-211M | $-208M | $-158M | $-158M | $-153M | $-150M | $-146M | $-144M | $-143M | $-142M | $-142M | $-141M | |
| AOCI | $-12M | $-12M | $-12M | $-12M | $-12M | $-14M | $-16M | $-13M | $-15M | $-15M | $-14M | $-15M | $-14M | $-15M | $-15M | $-16M | |
| Stockholders' Equity | $7M | $10M | $14M | $14M | $16M | $15M | $63M | $65M | $67M | $69M | $73M | $74M | $75M | $74M | $72M | $72M | |
| Liabilities + Equity | $76M | $78M | $80M | $78M | $80M | $80M | $127M | $131M | $129M | $133M | $137M | $140M | $143M | $146M | $145M | $147M | |
| Shares Outstanding | 4,552,305 | 4,510,182 | 44,719,894 | 44,579,665 | 44,531,198 | 44,213,746 | 44,074,475 | 43,616,621 | 43,610,883 | 43,421,251 | 43,394,509 | 42,688,246 | 42,688,246 | 42,190,043 | 42,081,707 | 41,657,688 |
현금 흐름 11
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $380.0K | $257.0K | $459.0K | $324.0K | $472.0K | $600.0K | $961.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| Amort. of Intangibles | $820.0K | $820.0K | $850.0K | $855.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | |
| Restructuring | $318.0K | $235.0K | $29.0K | $48.0K | $30.0K | $93.0K | $225.0K | $179.0K | $396.0K | $0 | · | · | · | · | $485.0K | $1M | |
| Operating Cash Flow | $325.0K | $-662.0K | $-96.0K | $1M | $3M | $3M | $2M | $-842.0K | $-846.0K | $1M | $4M | $4M | $4M | $2M | $3M | $649.0K | |
| CapEx | $688.0K | $426.0K | $449.0K | $207.0K | $89.0K | $513.0K | $301.0K | $880.0K | $818.0K | $645.0K | $830.0K | $217.0K | $517.0K | $224.0K | $235.0K | $442.0K | |
| Investing Cash Flow | $-916.0K | $-620.0K | $-599.0K | $-348.0K | $-233.0K | $-683.0K | $-466.0K | $-1M | $458.0K | $-225.0K | $-1M | $-401.0K | $-625.0K | $288.0K | $-235.0K | $-442.0K | |
| Net Debt Issued | · | $0 | · | · | · | $-1M | · | · | · | $-3M | · | · | · | $-2M | · | · | |
| Financing Cash Flow | $-38.0K | $-9.0K | $2M | $-1M | $-1M | $-1M | $-1M | $2M | $177.0K | $-1M | $-4M | $-3M | $-2M | $-3M | $-3M | $377.0K | |
| Net Change in Cash | $-595.0K | $-2M | $2M | $-625.0K | $2M | $1M | $-461.0K | $521.0K | $-207.0K | $-28.0K | $-1M | $1M | $535.0K | $-719.0K | $-636.0K | $885.0K | |
| Taxes Paid | $-164.0K | $-5.0K | $-144.0K | $-2.0K | $46.0K | $2.0K | $-474.0K | $184.0K | $105.0K | $26.0K | $39.0K | $53.0K | $249.0K | $-134.0K | $41.0K | $141.0K | |
| Free Cash Flow | · | $-1M | · | · | · | $2M | · | · | · | $758.0K | · | · | · | $2M | · | · |
수익성 8
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.6% | 59.0% | · | 58.4% | 56.4% | 56.0% | · | 58.1% | 57.2% | 60.3% | · | 58.1% | 58.0% | 61.2% | · | 45.2% | |
| Operating Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| Net Margin | -12.8% | -16.5% | · | -6.0% | -11.2% | -231.2% | · | -21.9% | -12.7% | -19.1% | · | -4.9% | -3.4% | 2.1% | · | -12.7% | |
| Pretax Margin | -12.7% | -15.9% | · | -5.5% | -11.0% | -233.3% | · | -20.4% | -14.2% | -18.3% | · | -2.2% | -7.3% | 4.0% | · | -17.4% | |
| EBITDA Margin | -4.3% | -5.7% | · | 0.96% | -4.0% | -228.1% | · | -8.5% | -9.0% | -9.3% | · | -3.7% | 2.8% | 5.8% | · | -14.0% | |
| ROA | -3.7% | -4.3% | · | -1.2% | -2.2% | -47.3% | · | -3.5% | -2.1% | -3.4% | · | -0.86% | -0.66% | 0.41% | · | -2.3% | |
| ROE | -25.1% | -27.5% | · | -3.1% | -5.5% | -120.4% | · | -6.9% | -4.1% | -6.6% | · | -1.7% | -1.3% | 0.83% | · | -4.6% | |
| ROIC | -2.2% | -2.6% | · | 1.5% | -5.3% | -331.8% | · | -1.9% | -1.8% | -2.3% | · | -1.8% | 0.32% | 0.76% | · | -2.2% |
유동성 및 지급능력 4
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.0 | · | 0.8 | 0.8 | 0.8 | · | 2.1 | 2.1 | 1.9 | · | 2.1 | 2.3 | 2.3 | · | 2.4 | |
| Quick Ratio | 0.8 | 0.9 | · | 0.3 | 0.4 | 0.3 | · | 0.8 | 0.7 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 0.9 | |
| Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.6 | 0.5 | 0.5 | · | 0.5 | 0.6 | 0.6 | · | 0.7 | |
| LT Debt / Equity | 4.9 | 3.6 | · | · | · | · | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.6 | · | 0.6 |
효율성 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.6 | |
| Receivables Turnover | 1.7 | 1.5 | · | 1.7 | 1.7 | 1.5 | · | 1.6 | 1.6 | 1.5 | · | 1.7 | 1.7 | 1.6 | · | 1.6 |
가치 평가 (TTM) 14
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $84M | · | $85M | $87M | $91M | · | $95M | $102M | $109M | · | $111M | $115M | $115M | · | $115M | |
| Net Income TTM | $-10M | $-57M | · | $-59M | $-60M | $-63M | · | $-14M | $-10M | $-6M | · | $-5M | $-1M | $-7M | · | $-8M | |
| Market Cap | $28M | $22M | · | $20M | $20M | $25M | · | $117M | $124M | $184M | · | $184M | $234M | $177M | · | $107M | |
| Enterprise Value | $58M | $51M | · | · | · | · | · | $151M | $156M | $216M | · | $217M | $272M | $218M | · | $151M | |
| P/E | -3.1 | -0.4 | · | -0.3 | -0.3 | -0.4 | · | -8.4 | -12.4 | -28.3 | · | -35.8 | -183.0 | -23.3 | · | · | |
| P/S | 0.3 | 0.3 | · | 0.2 | 0.2 | 0.3 | · | 1.2 | 1.2 | 1.7 | · | 1.7 | 2.0 | 1.5 | · | 0.9 | |
| P/B | 3.8 | 2.2 | · | 1.4 | 1.2 | 1.7 | · | 1.8 | 1.8 | 2.7 | · | 2.5 | 3.1 | 2.4 | · | 1.5 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | 189.4 | 897.9 | · | · | · | |
| P / Cash Flow | · | -33.2 | · | · | · | 8.4 | · | · | · | 131.2 | · | · | · | 97.8 | · | · | |
| P / FCF | · | -20.2 | · | · | · | 10.2 | · | · | · | 242.9 | · | · | · | 111.6 | · | · | |
| EV / EBITDA | -59.5 | -43.5 | · | · | · | · | · | -80.6 | -75.5 | -94.7 | · | -232.8 | 341.4 | 124.5 | · | -40.1 | |
| EV / FCF | · | -46.9 | · | · | · | · | · | · | · | 284.6 | · | · | · | 137.1 | · | · | |
| EV / Revenue | 0.7 | 0.6 | · | · | · | · | · | 1.6 | 1.5 | 2.0 | · | 2.0 | 2.4 | 1.9 | · | 1.3 | |
| Earnings Yield | -31.9% | -251.9% | · | -302.3% | -311.4% | -250.9% | · | -11.9% | -8.1% | -3.5% | · | -2.8% | -0.55% | -4.3% | · | · |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $87M | $94M | $112M | $113M | $119M |
| 매출 총이익률 % | 57.7% | 58.2% | 58.9% | 53.7% | 56.9% |
| 영업이익률 % | -56.1% | -6.6% | 1.7% | -6.1% | 1.7% |
| 순이익 | $-57M | $-12M | $-3M | $-10M | $-288.0K |
| 희석 EPS | $-1.28 | $-0.28 | $-0.08 | $-0.23 | — |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | 2.6 | 0.6 | 0.5 | 0.7 | 0.6 |
| 유동비율 | 2.2 | 0.8 | 1.8 | 2.2 | 2.4 |
| 당좌 비율 | 1.1 | 0.3 | 0.8 | 0.9 | 1.2 |
현금 흐름
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $5M | $-1M | $12M | $-438.0K | $67.0K |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 9개의 제출자 · $5.5M 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 0 (0 이전 분기 대비) | 0 (-57 이전 분기 대비) | 2 (+2 이전 분기 대비) | 0 (-3 이전 분기 대비) | +90K |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| AMH Equity Ltd | $1,774,844 | 4,047,535 | 32.20% | 주식 |
| Meros Investment Management, LP | $1,125,401 | 182,992 | 20.41% | 주식 |
| VANGUARD GROUP INC | $1,092,570 | 1,633,139 | 19.82% | 주식 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $879,954 | 143,082 | 15.96% | 주식 |
| TWO SIGMA ADVISERS, LP | $587,578 | 878,556 | 10.66% | 주식 |
| Nuveen Asset Management, LLC | $40,837 | 19,354 | 0.74% | 주식 |
| Point72 Asia (Singapore) Pte. Ltd. | $6,445 | 14,697 | 0.12% | 주식 |
| WOLVERINE TRADING, LLC | $5,102 | 11,600 | 0.09% | 콜 옵션 |
| Financial Connections Group, Inc. | $0 | 30 | 0.00% | 주식 |
회사 내부자 35 명의 내부자 · 14 임원 · 18 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| John D Duke | Chief Executive Officer | 2026년 3월 20일 A | 180,000 | 1 | 0 | $25,050 |
| Jeffrey Duchemin | Chief Executive Officer | 2019년 7월 7일 D | 464,528 | 0 | 0 | $0 |
| Mark T Frost | Chief Financial Officer | 2026년 3월 20일 A | 47,500 | 1 | 0 | $25,000 |
| Jennifer Cote | Chief Financial Officer | 2025년 3월 19일 F | 159,019 | 0 | 0 | $0 |
| Michael A. Rossi | Chief Financial Officer | 2022년 12월 29일 F | 260,540 | 0 | 0 | $0 |
| Kamalam Unninayar | Chief Financial Officer | 2019년 3월 7일 A | 73,858 | 0 | 0 | $0 |
| Bryce Anthony Chicoyne | Chief Financial Officer | 2007년 5월 1일 A | — | 0 | 0 | $0 |
| Mark A Norige | President, Harvard Apparatus | 2007년 5월 1일 A | — | 0 | 0 | $0 |
| David L Strack | President of Subsidiary | 2005년 5월 25일 A | — | 0 | 0 | $0 |
| Kenneth Fletcher Olson | Chief Operating Officer | 2021년 12월 29일 F | 155,595 | 0 | 0 | $0 |
| Yash Singh | Executive Vice President | 2019년 10월 31일 A | 39,286 | 0 | 0 | $0 |
| Yong Sun | VP - Commercial Operations | 2019년 1월 1일 F | 242,805 | 0 | 0 | $0 |
| Yoav Sibony | VP - Global Sales | 2015년 8월 3일 A | 21,582 | 0 | 0 | $0 |
| Paul Bailey | VP, Finance & Admin. | 2005년 5월 25일 A | — | 0 | 0 | $0 |
| Seth Benjamin Benson | 이사 | 2026년 6월 9일 A | 27,556 | 0 | 0 | $0 |
| Katherine A. Eade | 이사 | 2026년 6월 9일 A | 58,669 | 0 | 0 | $0 |
| Robert E. Gagnon | 이사 | 2026년 6월 9일 A | 27,556 | 0 | 0 | $0 |
| William Snider | 이사 | 2026년 6월 9일 A | 48,556 | 2 | 0 | $103,604 |
| Stephen J Denelsky | 이사 | 2026년 6월 9일 A | 37,556 | 1 | 0 | $48,700 |
| James W Green | 이사 | 2025년 8월 15일 D | 2,452,566 | 0 | 0 | $0 |
| Thomas W Loewald | 이사 | 2024년 5월 21일 A | 295,311 | 0 | 0 | $0 |
| Bertrand Loy | 이사 | 2024년 5월 21일 A | 56,575 | 0 | 0 | $0 |
| Alan I Edrick | 이사 | 2024년 5월 21일 A | 273,911 | 0 | 0 | $0 |
| John F Kennedy | 이사 | 2021년 3월 23일 G | 323,344 | 0 | 0 | $0 |
| Susan M. Steele | 이사 | 2021년 1월 4일 A | 49,400 | 0 | 0 | $0 |
| George Uveges | 이사 | 2018년 3월 12일 M | 142,685 | 0 | 0 | $0 |
| Earl R Lewis | 이사 | 2018년 1월 2일 A | 477,050 | 0 | 0 | $0 |
| David Green | 이사 | 2017년 2월 7일 S | 925,571 | 0 | 0 | $0 |
| Neal J Harte | 이사 | 2016년 5월 25일 M | 106,399 | 0 | 0 | $0 |
| Robert A Dishman | 이사 | 2015년 4월 28일 A | 51,055 | 0 | 0 | $0 |
| Chane Graziano | 10% 소유주 | 2013년 11월 7일 G | 3,005,150 | 0 | 0 | $0 |
| HARVARD BIOSCIENCE INC | 10% 소유주 | 2013년 11월 1일 J | 0 | 0 | 0 | $0 |
| HSO LIMITED PARTNERSHIP | 10% 소유주 | 2008년 5월 16일 S | 2,757,257 | 0 | 0 | $0 |
| Thomas Mcnaughton | — | 2013년 11월 1일 J | 171,613 | 0 | 0 | $0 |
| Susan M Luscinski | — | 2013년 11월 1일 J | 469,720 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 5 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider | 2026년 3월 23일 | 15.97% | 최초 제출 | — | SEC |
| ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 제출 서류 | 2020년 6월 22일 | — | 최초 제출 | — | SEC |
| HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 제출 서류 | 2008년 5월 20일 | — | 최초 제출 | — | SEC |
| 2007년 12월 14일 | — | 최초 제출 | — | SEC | |
| 미공개 보고자 | 2002년 7월 29일 | — | 최초 제출 | M&A / 매각 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 2 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.